Medterra BOGOF on CBD Oil: Use The Code SAMPLE At Checkout!

CBD Law

Are CBD Gummy Bears Legal?

CBD gummy bears offer a fun and delicious way to enjoy CBD, but are they legal?

In this 2021 Update, we’ll walk you through everything you need to know about CBD gummies, from the basics to the legalities, as well as our top recommendations.

What Are CBD Gummies?

CBD gummy bears, or CBD gummies in general, are a form of CBD edibles.

They were introduced in the US as an innovative way to take both CBD and medical/recreational cannabis (which is not yet legal in the UK). The public took to them very quickly thanks to their appealing image, taste, colour, and optimal convenience.

There are many ways a CBD gummy can be presented, and they can vary in dosage, size, shape, colour, and flavour. Therefore, you have many different options if you want to begin your CBD journey with CBD gummies.

In addition, different companies make their CBD gummies different ways; you can find all natural gummies, very high dosage gummies, even sour or sugar-coated gummies.

As you can see, you’ll never have a dull moment when it comes to CBD gummies!

Are CBD Gummy Bears Legal in the UK?

As of November 1st, 2018, CBD is a legal substance in the UK. Therefore, all products which contain CBD are also legal – including CBD gummies.

As you may already know, there are some rules and regulations which CBD must comply with when sold in the UK. These regulations include making sure the CBD had less than 0.2% THC content, and CBD gummies are no exception to this rule.

Update: 13th February 2020. The UK Food Standards Agency released new guidance on the legality of CBD products requiring all products on the market to submit a Novel Foods application by 31st March 2021 in order for them to remain legal.

It is currently not legal for there to be more than 1mg THC per packet of gummies sold in the UK or 0.01% THC.

Curious About CBD Laws? Learn More: Is It Legal To Grow CBD (Hemp) Plants In The UK?

All of the CBD gummies you see on our site are 100% legal and approved, made by well known and loved CBD brands. We offer an excellent variety of CBD gummies to choose from, so we hope you find exactly what you are looking for.

Why Are CBD Gummies So Popular?

CBD gummies, as mentioned at the beginning of this blog, are popular thanks to the variety of options available: their appealing names, flavours, and colours.

They are also super convenient to consume and are discrete…

They are, as you can imagine, very easy to grab and go about your day with. Perfectly disguised thanks to their common appearance. Gummies are also great for people who don’t have the time or patience to measure out each dose throughout the day. Furthermore – they are very easy to take in any public space.

Additionally, CBD gummy bears just taste great, compared to the grassy and earthy taste found in pure oils.

Pros and Cons of CBD Gummy Bears

Like everything, though, CBD gummy bears have pros and cons, and below we mention the top 3 for each category:

Pros

Cons

CBD Gummies We Recommend

Zenbears CBD Gummies

Zenbears CBD Gummies

Are these our favourite CBD Gummies? Possibly. The Zenbears Gummies taste excellent and are packed full of good vibes. We love the ...

from £33.96
4.5
CBDfx CBD Gummy Bears

CBDfx CBD Gummy Bears

With the demand for hassle-free, accessible ways of consuming CBD on the rise, CBD gummies have become one of the most common ...

from £35.99
Is it Legal to Buy CBD Flowers in the UK?

We are trying to make these laws clearer, and hoping to guide you in these uncertain times. As different issues arise, we want you to know what to do to stay within the UK’s laws in order to stay safe.

The latest question to arise has been whether or not it is legal to buy, own, or distribute CBD flowers in the UK. Well, this is all you need to know.

Must ReadUK CBD Law – An In-depth Analysis

What are CBD Flowers?

So, what exactly are CBD flowers anyway? Actually, the term “CBD flowers” refers specifically to hemp flowers that are incredibly high in CBD (around 13-15%) and low in THC (usually less than 0.2%).

Thanks to altering strains of hemp over a period of time, there are now a few strains of hemp that produce these CBD-rich flowers, but still produce the low THC which hemp is known for.

CBD flowers have been incredibly popular lately in countries such as the US because they are so high in CBD and so low in THC. Thanks to this they are within the country’s laws regarding THC content, but they also provide a very large amount of CBD.

CBD Flowers

CBD Flowers and UK Law

CBD flowers are illegal to buy and sell in the UK. The exact reason can sound a bit confusing, but this is what you need to know:

This means that even though hemp flowers may fit into the legal THC limit that CBD must comply with (less than 0.2%) and is non-psychoactive; since they are a part of the cannabis plant, they are illegal.

But this hasn’t stopped people from selling CBD flowers online in the UK. Unfortunately, there are vendors online who sell “CBD flowers” to people who don’t realise that they are illegal.

This has posed a huge problem for both the vendors and the buyers because the vendors are then involved in the sale of illegal and controlled substances, and the buyers are guilty of purchasing and possessing them.

As of now, the British Government is doing all it can to make sure that people know with certainty that CBD flowers, buds, hash and resin are illegal in the UK, no matter what vendors try to tell you.

Of course, the Government has made many efforts to control these incidents, but educating the public on the laws surrounding cannabis products is one of the best ways to avoid these situations altogether.

Illegal CBD Flowers

How to Safely Shop for CBD Online in the UK

The majority of CBD sales in the UK happen online. This is a great thing because it is easy and simple, and many sites offer a lot of information on their products and the CBD experience in general.

This can also pose a bit of a risk because there could be a risk of buying CBD flowers without even knowing they are illegal. Especially since some vendors can be pretty convincing sometimes. However, it is a rare occurrence and now that you’re reading this, you know that CBD flowers are illegal.

Suggested ReadHow Safe Is Vaping CBD?

All the same, there are so many other CBD products that are perfect for those of you who would like to add CBD to your daily lives. There is no need to be afraid of all CBD just because CBD/hemp flowers are illegal! Here are some tips for finding the best CBD for you (safely!):

We know that cannabis and hemp laws have been changing in the UK recently. This is conflicting because it can become confusing, and the line between what is legal and what is illegal can become increasingly harder to distinguish.

Just remember that CBD/hemp flowers are illegal to buy or sell at the moment, while the majority of other CBD products are safe and legal, so don’t shy away from all the other amazing CBD products available!

Where Can I Buy CBD Joints Legally?

Still keen on CBD flower?

Why not try The Goods CBD Pre-Rolls which offer a legal way of smoking CBD in the way you want.

Offering a mixture of herbs with CBD content added separately, The Goods pre-rolled CBD joints are a fully legal way of enjoying CBD in this way.

The Goods CBD Pre-Rolls

The Goods CBD Pre-Rolls

The Good's have released a range of 10% pre-rolled CBD Spliffs. These Spliffs have been carefully formulated to ensure they aren't breaking ...

from £8.99
Where Is CBD Legal?

With the rising popularity of CBD and the growing number of users, more questions are being asked about the popular substance. Not only do people want to know more about what this substance has to offer, but also if they can benefit from it themselves.

One of the main things that is putting a real obstacle in peoples way when it comes to enjoying the benefits of CBD is legality. Yep, that’s right. CBD might be one of the most popular topics at the moment and may be taking the trend spotlight, but that does not mean it is legal everywhere?

Curious About CBD Laws? Learn More: UK CBD Law – An In-depth Analysis

CBD

What is CBD?

CBD is one of the main cannabinoids found in the cannabis and hemp plant. One of the main things that has caused people to believe that CBD is an illegal substance ‘everywhere’, is the fact that it comes from cannabis and hemp. However, CBD is different from other cannabinoids; like THC for example.

THC is also a cannabinoid, but there is one key thing that makes THC and CBD different from each other; psychoactivity. THC is famous for causing psychoactive effects or a “high” in users. CBD however, does not cause psychoactive effects.

CBD’s non-psychoactivity has allowed it to be legalised more ‘easily’ than THC. It has also allowed people to understand that CBD is meant to be used in a different way than THC, and it’s not just a ‘drug’ for ‘thrill seekers’.

Where is CBD Legal?

Although CBD being legal worldwide would make it easier for thousands of CBD users to enjoy their beloved substance, things are simply not that easy. The illegality of cannabis and hemp growth production has made the legality of CBD complicated, thus leaving CBD’s legality in a ‘grey area’.

Because of the ‘touchy’ legality of cannabis, there is an even more complicated process for CBD users that prefer cannabis-derived CBD, as opposed to hemp-derived CBD.

Another thing that makes the legality of CBD complicated is the different types of CBD products. Those that contain higher levels of THC can be illegal, but products that contain lower levels of THC are legal.

At times it can be quite difficult to find out the legal status of CBD in certain countries. While the United Kingdom and Canada seem easy enough to find information on, the United States is a whole different story as the laws change from state to state.

United Kingdom – One of the ‘hotspots’ for growing CBD companies and CBD communities is the UK. Thanks to the legalisation of CBD in 2018, thousand of CBD lovers in the UK are finally able to enjoy any CBD products that does not exceed the THC limit of 0.2%.

Canada– Thanks to the legalisation of cannabis on a recreational basis, CBD products of all descriptions are easy to find in Canada, and because of this, there is a flourishing community of CBD users and CBD companies.

United States – Although individual states of the USA make their own unique laws regarding the production and selling of CBD products, many of them allow the legal recreational use of marijuana, thus making CBD legal. These states include Alaska, California, Colorado, Maine, Massachusetts, Nevada, Oregon, Vermont, and Washington.

While some states don’t allow the recreational use of cannabis, there are others that do allow some types of CBD products, majorly hemp-derived CBD including Oklahoma, New Mexico, New Jersey, New Hampshire, Georgia, Delaware, Florida and Connecticut.

World Map

List of Countries that Allow the Sale of CBD

Along with the above three countries, below is a list of countries that do allow the sale of CBD products that we know of. Please note, that this list is just a guideline and can change at any given moment depending on regulation changes in any of these countries.

European Countries

Asia

North America

South America

Africa

As mentioned before, this list is just a guideline of countries that we do know that the sale of CBD is legal and can change at any given moment. Also, while somf of the countries that haven’t made it to the list, this doesn’t necessarily mean CDB is illegal in them. It just means that their regulations are very unclear or the info is just not easily accessible. 

If you are looking to purchase CBD or bring CBD into a country that you are not sure of, always double-check the legal status first. 

CBD Legality

The Future of CBD’s Legalisation

Thanks to the growing demand of CBD, it seems that this popular compound has a bright future. Not only are more people wanting to learn more about this natural compound, but are also asking “when will we get the chance to enjoy it in our country too?!”.

Well, thanks to this interest, and the positivity of the CBD community, its worldwide legality might actually become a reality in a not so far away future. Another thing that might allow CBD to become more widely used and legalised is more proof and studies done on the cannabinoid.

The more that we learn about the cannabinoid, and what benefits it can offer users, the better. Even if we now only have limited information, and are still in a slight ‘grey’ area about what this compound can do, we have discovered many good things.

We hope to soon know more about CBD, what it can offer us, and how it can make our future brighter, and with this, we also hope to soon see it be legalised in more countries worldwide, so that a larger number of CBD lovers can enjoy this trendy compound.

UK CBD Law – An In-Depth Analysis

This In-depth Analysis of CBD Law In the United Kingdom was developed to help both consumers understand what is required of the CBD products they consume to be legal and for brands navigate the many legal barriers to entry into the UK CBD Market.CBD Law in the UK is quite complex and constantly evolving. It is essential to us here at Bloom Botanics to make sure that we are up to date on the current legal status of CBD and cannabis/hemp extracts. This is to ensure that we are selling our customers legal and lab-tested products in the UK. Keeping ourselves and our customers legally safe.

– Bloom Botanics Team

Table of Contents:

  1. Introduction: Relevant Laws.
  2. Is CBD a Scheduled potentially illegal non-ethical drug in the United Kingdom? (In many cases, this is likely the case.)
  3. Is CBD a medicine in the UK and, therefore, regulated as a medicine? (In many cases, this may well be likely)
  4. CBD and issues regarding “Cannabis-Based Products for Medicinal Use in Humans (CBPM)s –Regulation 2 and Schedule 2 MDR 2001” (This generally does not refer to pure CBD. In fact, at this time, in the UK it is also not relevant to CBD in a format which includes any amount of THC, and has not been approved as a drug, or is not prescribed by a specialist physician)
  5. CBD as a food or food supplement in the United Kingdom
  6. The Centre for Medicinal Cannabis

1.  Introduction: Relevant Laws:

Pure CBD appears excluded from being a controlled drug in the UK. However, a multitude of specific laws and regulations must be followed and further, the CBD product can contain in total no more than 1 mg of THC, which is essentially zero concentration by weight.

Class A Drugs are controlled under various acts in the United Kingdom including the Misuse of Drugs Act 1971. The 1971 Act applies to “Controlled Drugs”. This includes substances or products specified in Schedule 2 to the Act.

That Schedule divides controlled drugs into one of three classes: A, B and C – broadly based on their relative harms, with Class A drugs considered the most harmful. Examples of each class of drug are:

“Cannabinol derivatives” means, except where contained in cannabis or cannabis resin, tetrahydro derivatives of cannabinol and 3-alkyl homologs of cannabinol or of its tetrahydro derivatives”. Cannabis Oil is also considered “Class B“.

Regarding definitions of terms, it should be noted that in biologically (concepts and terms of which are applicable legally, unless specifically redefined under legislation or related regulations) Hemp Plants are in the Cannabis Sativa species and therefore are Cannabis.

See Also: van Bakel, H., Stout, J.M., Cote, A.G. et al. The draft genome and transcriptome of Cannabis sativa. Genome Biol 12, R102 (2011) doi:10.1186/gb-2011-12-10-r102 .)

2.  Is CBD a Scheduled potentially illegal non-ethical drug in the United Kingdom?

Introduction:

Please note that the term “ethical drug“ is defined to be a prescription drug that is only available with written instructions from a doctor or dentist to a pharmacist. Based on the review of the Home Office documentation, all referenced below, one could conclude that CBD is a Class B controlled drug, however, legal opinions are being offered that pure CBD is excluded from the Misuse of Drugs Act.

Suggested Reads: Field fisher, 10 Things you should know about Medicinal Cannabis in the UK & Reed Smith LLP, “Cannabis in the UK – a regulatory environment in transition?” & Home Office Interpretation of Legislation and Regulations Regarding Cannabis, CBD, and Other Cannabinoids

The following views are extracted from Drug Licensing Factsheet – Cannabis, CBD and other Cannabinoids, published on the worldwide web and dated August 26, 2019. The Government preamble to the Guidance, called ““Cannabis, CBD and other cannabinoids: drug licensing factsheet” states: “This factsheet outlines the domestic control measures that apply to cannabis, cannabidiol (CBD) and controlled cannabinoids.” According to the UK government statements on the web at that location:

“This factsheet is intended to be used by existing licensees and prospective licensees who may need to apply for a licence. They should have fully assessed any proposals they may wish to make in the context of this guidance and that provided by other regulators.”

“ This is intended as general guidance only; it is not legal advice. Anyone in doubt should seek their own independent legal advice to ensure they are compliant with any relevant legislation.”

“This factsheet represents the Home Office’s view on the domestic control measures applicable to cannabis, cannabidiol (CBD) and controlled cannabinoids. It is intended as a resource for existing licensees and prospective licensees who may need to apply for a licence, having fully assessed any proposals they may wish to make in the context of this guidance and that provided by other regulators.”

“There are two separate licensing regimes relating to cannabis cultivation, according to whether the varieties are high or low THC (as differentiated in the Misuse of Drugs (Fees)

Regulations 2010). This factsheet may also be read in conjunction with published guidance relating to low- THC Industrial Hemp cultivation and use of non-controlled hemp products from fibre and seed is available at https://www.gov.uk/government/collections/drugs-licensing#industrial-hemp.

Home Office General Legislative Position on Cannabis and “Cannabis-based products for medicinal use in humans”:

“Cannabis is a Class B controlled drug under Part II, Schedule 2, of the Misuse of Drugs Act 1971 (MDA 1971). It is also listed in Schedule 1 to the Misuse of Drugs Regulations 2001 (MDR 2001) and designated under the Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015 (2015 Order). As such, it is unlawful to possess, supply, produce, import or export this drug except under a Home Office licence. It is also an offence to cultivate any plant of the genus Cannabis except under a Home Office licence.”

The Misuse of Drugs Regulations 2001 is located at www.legislation.gov.uk/uksi/2001/3998/regulation/2/made.

The regulations are with respect to the Misuse of Drugs Act 1971. The Regulations are also at www.legislation.gov.uk/uksi/2001/3998/pdfs/uksi_20013998_en.pdf.

“Cannabis-based products for medicinal use in humans” (“CBPM”) -a defined category of cannabis, cannabis resin, cannabinol and cannabinol derivatives -are listed in Schedule 2 to the MDR 2001 and removed from designation under the 2015 Order.”

Under Schedule 1 to the 2001 Regulations are included: Cannabinol, Cannabinol derivatives not being dronabinol and its isomers, and cannabis resin, and their isomers, esters, and salts, and any preparation of other products containing such substances except as excluded in Schedule 5.

Based on the analysis below, and additional analysis regarding hemp (further below) it would seem that selling pure CBD, but not as a medicine, but in conjunction with some carrying substance, could be legal in the UK. Related factors include the source of the CBD, whether it is regarded as a food

According to the Home Office Statement:

“CBD as an isolated substance, in its pure form, would not be controlled under the MDA 1971 / MDR 2001.”

“If a CBD ‘product’ contained any controlled cannabinoids, unintentionally or otherwise (e.g. THC or THC-V), then it is highly likely that the product would be controlled. It is our understanding that it is very difficult to isolate pure CBD, and in our experience many products in fact do not fully disclose their contents or provide a full spectrum analysis at an appropriate

level of sensitivity to accurately and consistently determine their true content or control status”.

“Against this background, the presumption has to be one of caution -that is, that a CBD containing product would be controlled under the MDA 1971 / MDR 2001 as a result of its other cannabinoid content.”

“In addition to any issues associated with controlled substance content, cannabis/ cannabis extract products may also need to satisfy other regulatory requirements if clinical/medicinal benefits are claimed. In this respect, companies may wish to contact the MHRA for their view on whether the cannabis/ cannabis extract products are additionally subject to their licensing regime and control.”

The Home Office Statements also includes the following:

“For a CBD and other cannabinoid products to be lawfully available for human consumption, it needs to either meet the Exempted Product Criteria in Regulation 2 of the MDR 2001 or the definition of a CBPM in Schedule 2 to the MDR2001 for its possession to be lawful.”

“Where a product is neither a CBPM nor an ‘Exempted Product’, licenses would not ordinarily be issued to enable the use of a ‘Schedule 1’ controlled drug product outside of bonafide research or a recognised UK clinical trial.”

“The ‘exempted product’ definition -Regulation 2 of the MDR 2001”

Regulation 2 (Interpretation) to the Misuse of Drugs Act 1971 “provides that some products may, in limited circumstances, be considered ‘exempt’ from control, notwithstanding their ‘controlled drug’ content.”

“The regulation sets out: An “exempt product” means a preparation or other product consisting of one or more component parts, any of which contains a controlled drug, where—

  1. the preparation or other product is not designed for administration of the controlled drug to a human being or animal;
  2. the controlled drug in any component part is packaged in such a form, or in combination with other active or inert substances in such a manner, that it cannot be recovered by readily applicable means or in a yield which constitutes a risk to health; and
  3. no one component part of the product or preparation contains more than one milligram of the controlled drug or one microgram in the case of lysergide or any other N-alkyl derivative of lysergamide.”

“To meet the criteria of an exempted product all three limbs of the definition must be met.”

“The Home Office view is that this definition may apply to drug preparations or products in any form-for example an Active Pharmaceutical Ingredient (API) or a medicinal product in Finished Dose Form (although it is highly likely that in a ‘bulk form’ the 1mg threshold would cease to be met).”

“It is the Home Office view that, to establish that the definition is met, testing e.g. a full spectrum analysis to the appropriate threshold by an independent and licensed UK company, and provision of comprehensive and independently verifiable information and research of an appropriately rigorous nature will be required. It is likely that the product will be subjected to regulation as a medicinal product (or to an equivalent UK regulatory standard) as a way of demonstrating that there is no intention of administering the controlled drug element of the product (referred to in (a)). The purpose and intended method of administration of a product may affect this. It is the Home Office view that the applicable unit of measure for the 1mg ‘threshold’ referred to in (c) is that of the ‘container’ (i.e. bottle or packet) and not the ‘typical dose’ (of any product).”

Conclusions regarding CBD Products Being a Controlled Drug:

I have drawn considerably from ReedSmith Pepper and Perry 2019 Client Alert .

Pure CBD is not a controlled drug under the Act or the Regulations. However, the Home Office’s position appears to be that it is very difficult to isolate pure CBD and remove any controlled cannabinoids, such as THC. The presence of THC (even in very small quantities) is highly likely to mean that CBD products intended for human or animal administration are controlled under both the Act and the Regulations. Thus, the Home Office’s approach seems to be that a Home Office license would be required to import, export, produce, supply or possess CBD products.

It is often stated on the web in “lay” commercial articles that CBD oil products with a THC content of less than 0.2% are legal and by implication that they may not require a Home Office license. This is totally false. The assertions confuse legally acceptable CBD product definitions with the laws related to the definition of hemp plants, for the purpose of obtaining licenses to grow hemp.

3.  Is CBD a medicine in the UK and therefore regulated as a medicine?

The following analysis was written in conjunction with material from otcexperts, company of healthcare and regulatory consultants in the United Kingdom

Even if a CBD-containing product is not subject to the controls of the Act or the Regulations, the UK’s medicines and medical devices regulator, the Medicines & Healthcare products Regulatory Agency (MHRA), has taken the view that “products containing cannabidiol (CBD) used for medical purposes are a medicine” and as such must have an MHRA product license (marketing authorization) before being made available to consumers, supplied or advertised unless they fall under the narrow exemptions of the Human Medicines Regulations 2012 (the exemptions

now include “CBPMs” (see below), subject to certain controls). To date, only one cannabis-based medicinal product, Sativex, (for the treatment of multiple sclerosis) has been licensed by the MHRA.

The MHRA has issued new guidance on Cannabidiol in October of 2018, ‘Guide to what is a Medicinal Product’. This is a primary document for products that fall within the borderline area. It sets out MHRA thinking based on new legislation and cases they have assessed. The MHRA does not state if a category is or is not legal, as it assesses any specifics based on the specifics of that defined product.

The Guide refers to virtually all relevant aspects of possible CBD product regulation as a medicine, food, food supplement, cosmetics, etc. However, its details only relate to medical product regulation.

In the October 2018 revised MHRA guide the changes are presented in Appendix 10, page 67. This appendix covers the MHRA position/guidance for Cannabidiol containing products, covering:

  1. CBD products for non-medical purposes;
  2. Compliance with other regulatory frameworks; and
  3. CBD products for medical purposes, including supply of an unlicensed medicine

(“a special”), and licensing.

According to the MHRA Guidelines as to what are medical products, “to protect public health, and on behalf of the UK Licensing Authority, the Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicinal products for human use in accordance with the European Community’s medicinal products directive (Directive 2001/83/EC, as amended, “the Directive”) and UK law. The MHRA may be asked to give an opinion on, or make a formal determination on whether a product is or is not a medicinal product. This is a specialist function carried out by classifiers in the MHRA’s Medicines Borderline Section. If a classifier does decide that a product is a medicinal product, then unless an exemption applies, it will be subject to the Human Medicines Regulations 2012 [SI 2012/1916] (“the Regulations”).”

“The person or company marketing a product has a responsibility to do so in accordance with the law. The Regulations provide that, unless exempt1, any medicinal product placed on the UK market must have a marketing authorisation (MA), traditional herbal registration (THR) or certificate of registration as a homoeopathic product granted by the European Commission or by the UK Licensing Authority. A marketing authorisation or registration is only granted for a medicinal product which meets statutory standards of safety, quality and efficacy, whilst products registered as traditional herbal medicines or as homoeopathic medicines have to meet statutory standards of safety and quality. Traditional herbal medicinal products are required to demonstrate plausible efficacy alongside other criteria. See Section 9 of this guidance note for further information on this aspect.”

MHRA – Borderline Products:

“The regulatory status of products on the borderline between medicinal products and food supplements, biocides, cosmetic products, medical devices or ‘general products’ may not be immediately obvious. This Guidance explains how, and on what basis, the MHRA decides whether products are medicines or not and clarifies the MHRA’s position on traditional herbal medicinal products.”

Click here to view the detail of approved products. 

“The MHRA, on behalf of the UK Licensing Authority, determines (subject to review by the courts), whether a product is a medicinal product. The MHRA’s power to determine the status of a product as a medicinal product has been confirmed following a judgment of the Court of Appeal (R. v. Medicines Control Agency ex parte Pharma Nord (UK) Limited 1998). The Court ruled that it was acceptable for the Licensing Authority to determine whether or not a product is a medicinal product, having expert knowledge, the decision of the Licensing Authority being subject to review by the courts. This authority is also cited in subsequent litigation cases.”

A medicinal product is defined as: “any substance or combination of substances presented as having properties for treating or preventing disease in human beings; [the first/presentational limb]” or “any substance or combination of substances which may be used in, or administered to, human beings, either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis” [the second/functional limb]”.

Food claims

“The Food Information to Consumers Regulation (FIC) (Regulation (EC) 1169/2011), contains provisions for both the labelling and advertising of food. In particular, any claim that a food has the property of preventing, treating or curing human disease is not permitted. This covers any implication that a foodstuff is capable of protecting against or relieving the symptoms of, disease, infection or other adverse conditions. The MHRA must, therefore, be mindful of the primary purpose of the product when investigating whether medicinal claims which are made for food products (including food supplements) should be subject to the Regulations. In addition, any nutrition or health claims made on food must now be authorized before use in the EU. The Nutrition and Health Claims Regulation (Regulation (EC) 1924/2006), sets out the requirements for authorization of claims for foods and the European Commission has established a register of permitted, rejected and pending nutrition and health claims.

“A product which the average consumer would regard as something to be eaten, drunk or chewed as part of a diet, because of its taste, flavour, or nutritional value etc., is unlikely to be classified by the MHRA as a medicinal product unless it contains one or more ingredients generally regarded as medicinal and indicative of a medicinal purpose. If the MHRA determines

that such a product is not a medicine, it is likely to be regulated under food law. However, a product which satisfies equally well the conditions for classification as a food and the conditions for classification as a medicinal product will generally be classified as a medicinal product taking into account all of the product’s characteristics.”

“The European Commission has issued specific guidance for food supplements in relation to the applicability of Regulation (EC) 764/2008, which concerns mutual recognition in the EU. This guidance is helpful in relation to borderline products, noting that there may be instances where a product is regarded to be a food supplement in one Member States and a medicinal product in another.”

Cannabis-based products for medicinal use in humans:

“Cannabis-based products for medicinal use in humans” (“CBPM”) -a defined category of cannabis, cannabis resin, cannabinol and cannabinol derivatives -are listed in Schedule 2 to the MDR 2001 and removed from designation under the 2015 Order.”

Under Schedule 1 to the 2001 Regulations are included: Cannabinol, Cannabinol derivatives not being dronabinol and its isomers, and cannabis resin, and their isomers, esters, and salts, and any preparation of other products containing such substances except as excluded in Schedule 5.

Appendix 10 to the Guidance, called “Guidance on Cannabidiol (CBD) Products” is presented directly below:

Introduction:

“In 2016 MHRA published an opinion that products containing CBD, when used for a medical purpose, should be regulated as medicinal products (https://www.gov.uk/government/news/mhra-statement-on-products-containing-cannabidiol-cbd ). The MHRA’s opinion was issued with the intention of seeking voluntary compliance by companies supplying CBD for medical purposes. This guidance has been published in response to a significant number of requests for regulatory advice regarding the sale of CBD products for non-medical purposes and is intended to supplement MHRA’s published opinion.”

Regulations:

“In the UK, as in the rest of the EU, medicinal products which are placed on the market, are required to have marketing authorizations in accordance with The Human Medicines Regulations 2012 (S.I. 2012/1916) (the Regulations). Amongst other things these provide that, unless exempt, no medicinal product shall be placed on the market unless an appropriate authorization has been granted in accordance with EU law by the licensing authority or the European Commission.”

“It is an offence to sell or supply or to advertise a medicinal product which does not have authorization. A “medicinal product”

is defined in Article 1 of Directive 2001/83/EC, which is implemented by Regulation 2 of the Regulations. The definition, which is in two ‘limbs’ is:

“Any substance or combination of substances presented as having properties for treating or preventing disease in human beings (Limb 1). Any substance or combination of substances which may be used in or administered to human beings either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis (Limb 2).”

“If a product satisfies either of the above criteria, it may be classed as a medicinal product. In broad terms, when classifying a product, the Agency looks at the way it is presented and its function, that is, its effects (when administered) on human physiology. The term “disease” is defined in Regulation 8 of the Regulations as: “includes any injury, ailment or adverse condition, whether of body or mind”. Where unauthorized products are marketed for a medical purpose MHRA will take appropriate action to achieve compliance. Where necessary, MHRA can use the statutory determination process described in Appendix 3 of this Guidance to formally classify a particular product. Any product that makes a medicinal claim would fall within Limb 1 of the definition. For the avoidance of doubt, this includes any testimonies that are included on websites or any other promotional material. Further guidance in relation to medicinal claims can be found in Appendices 1, 8 and 9 of this guidance.”

“It is a matter of fact that there have been a number of clinical trials which demonstrate that CBD has a therapeutic effect, particularly in the treatment of severe epilepsy. MHRA’s clinical assessors have reviewed relevant scientific and clinical evidence to support the mode of action of CBD in the treatment of a range of medical conditions. It should also be noted that the European Medicines Agency has given CBD products an orphan designation on four occasions, for three different clinical conditions; graft versus host disease, perinatal asphyxia and Dravet syndrome. An application for a CBD product (Epidiolex) is currently under assessment within the EU for use as adjunctive therapy of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients from 2 years of age.”

CBD products for non-medical purposes:

“The emerging evidence of clinical efficacy outlined above MHRA could, in future, regard certain CBD products, which may currently be marketed under other regulatory frameworks, to fall within the second limb of the definition of a medicinal product. Given this, MHRA can give no assurance that any particular product, including products under development, will not subsequently be classified as a medicinal product. Classification as a medicinal product overrides other regulatory frameworks and it is important that a company considering the marketing of CBD products as a non-medicine should be aware that the regulatory status of their product may change.”

Compliance with other regulatory frameworks:

“MHRA will never advise that a product is ‘legal’. This is because our remit is limited to the regulation of medicines and medical devices and any advice given in relation to CBD products will be in respect of classification as a medicinal product. Products which are not deemed to be medicines will be subject to other regulatory frameworks and it is the responsibility of those who manufacture and/or market a product to ensure that it complies with the relevant legislation. MHRAs encourage companies to seek advice from the relevant authorities.”

“Local Authority Trading Standards or Environmental Health Departments can advise on relevant aspects of food law (including food supplements). This may include, but not be limited to, registration as a food business operator, compliance with food hygiene regulations and products which might be regarded to be novel foods.”

“Products containing CBD that are intended to be placed in contact with the external parts of the human body with a view exclusively or mainly to fulfil a cosmetic function as per article 2 of the Cosmetic Products Regulation (EC) 1223/200913 must meet the regulatory requirements set out by this Regulation. Regulation (EC)1223/2009 ensures the safety of cosmetic products, their cosmetics ingredients (irrespective of their source) and protect consumers from misleading claims.”

“MHRA is occasionally asked whether claims can be made for CBD in respect of the endocannabinoid system. The endocannabinoid system is a neuromodulator system that has a role in central nervous system development and in regulating a variety of physiological and cognitive processes.”

“Claims which imply that CBD can modify, stimulate or enhance the endocannabinoid system (or similar) may in context, be regarded to be medicinal claims. Where claims are not regarded to be medicinal claims, companies are advised to be mindful of health claims legislation which applies to foods (Regulation (EC) 1924/200614) and/or check with Trading Standards or Environmental Health to see whether they can be used without prior approval.”

“Companies should be mindful that if products contain other cannabinoids, including at low levels, these may be regarded to be controlled substances. The Home Office has issued a factsheet, called ‘Cannabis, CBD and other cannabinoids’ which sets out the Exempted Product Definition and how these products should be regulated.

This can be accessed at the following website: https://www.gov.uk/guidance/controlled-drugs-licences-fees-and-returns .”

CBD Products for Medicinal Purposes:

“In the absence of any licensed CBD medicinal products, MHRA would advise individuals with underlying medical conditions who are using CBD to discuss this with their doctor who may prescribe medicinal products to appropriately manage the symptoms. Companies wishing to supply CBD products for a medical purpose should consider the following”:

“(i) Supply of an unlicensed medicine (a ‘Special’)”

A medicine is generally required to have a marketing authorization (product license) before being placed on the market. However, unlicensed medicinal products containing CBD could be made available to individuals on prescription, but this supply is subject to certain conditions. An unlicensed medicine can only be supplied to meet the special needs of an individual patient. Responsibility for deciding whether an individual patient has “special needs” (interpreted as clinical needs) which a licensed product cannot meet should be a matter for the prescriber responsible for the patient’s care. An unlicensed medicine may not be advertised, a manufacturer, importer or wholesaler may provide factual responses related to the supply of products but these cannot include medicinal claims. See MHRA Guidance Note 14 for further information regarding the sale and supply of unlicensed medicines. https://www.gov.uk/government/publications/supply-unlicensed-medicinal-products-specials 

“(ii) Obtaining a license to supply a licensed medicine”

“For general information on licensing applications, please refer to www.gov.uk/medicines-medical-devices-blood/marketing-authorisations-variations-licensing; https://www.gov.uk/guidance/apply-for-a-licence-to-market-a-medicine-in-the-uk. 

“Our Regulatory Information Service can also advise on how to submit new license applications on Tel: 020 3080 7400 or via email at [email protected] Where CBD is being considered for a clinical trial in humans (an MHRA responsibility) the material will need to be manufactured or imported by the holder of the appropriate manufacturer’s authorization for an investigational medicinal product, [known as an MIA(IMP)] and have a clinical trial authorization (CTA). These links may be helpful: www.gov.uk/government/collections/clinical-trials-for-medicines www.gov.uk/guidance/medicines-get-scientific-advice-from-mhra 

Summary:

“This guidance sets out MHRA’s current position in respect of the classification of CBD products. It also briefly covers the supply of CBD products as medicines. Companies need to be mindful of MHRA’s remit and ensure that they have obtained advice from all relevant regulators prior to placing products on the market.”

4. CBD and issues regarding “Cannabis Based Products for Medicinal Use in Humans (CBPM)s –Regulation 2 and Schedule 2 MDR 2001”

As previously stated and quoted from the Home Office Factsheet, “ for a CBD and other cannabinoid products to be lawfully available for human consumption it needs to either meet the Exempted Product Criteria in Regulation 2 of the MDR 2001 or the definition of a CBPM in Schedule 2 to the MDR2001 for its possession to be lawful. Where a product is neither a CBPM nor an ‘Exempted Product’, licences would not ordinarily be issued to enable the use of a ‘Schedule 1’ controlled drug product outside of bona-fide research or a recognised UK clinical trial.”

Cannabis Based Products for Medicinal Use in Humans (CBPM)s – Regulation 2 and Schedule 2 MDR 2001

Regulation 2 and Schedule 2 MDR 2001:

“With effect from 1 November 2018, CBPMs will be listed in Schedule 2 to the MDR 2001.”

“Regulation 2 of the MDR 2001 http://www.legislation.gov.uk/uksi/2018/1055/contents/made defines CBPMs as: “cannabis-based product for medicinal use in humans” means a preparation or other product, other than one to which paragraph 5 of part 1 of Schedule 4 applies, which—

“A CBD preparation or product containing controlled cannabinoids (e.g. THC) which meets the three limbs of this definition may be a CBPM.”

“Specialist Doctors can prescribe CBPMs without requiring a Home Office licence to lawfully write a prescription. However, as with other controlled drugs in Schedule 2, companies wishing to possess, supply, produce, manufacture and/ or import/ export these products will require Home Office Controlled Drug licences to lawfully undertake these activities, unless a limited licensing ‘exemption’ applies -e.g. a pharmacist or person conducting a retail pharmacy business acting in their respective capacities (however see guidance here on wholesale dealing: https://www.gov.uk/guidance/controlled-drugs-licences-fees-and-returns). It should be noted that Regulation 16A of the MDR 2001 imposes additional controls for the order and supply of CBPMs for the purpose of administration.”

“Where a preparation or product containing cannabis, cannabis resin, cannabinol or a cannabinol derivative does not meet the definition of a CBPM, it will be a Schedule 1 drug under the MDR 2001 unless the exempt product definition applies. “

5.  CBD as a Food or Food Supplement in the United Kingdom:

The EU publications regarding CBD as a novel food has been relevant to food authorities in the United Kingdom. According to the law firm Arnold and Porter in EU Regulation of CBD in Foodsand Cosmetics August 15 2019, the EU position (As of 1 January 2018, the new Regulation (EU) 2015/2283 on novel foods (the Novel Food Regulation) is applicable. It repeals and

replaces Regulation (EC) No 258/97 and Regulation (EC) No 1852/2001 which were in force until 31 December 2017) is “Under European Union law, food that has not been consumed to a significant degree by humans in the EU before 15 May 1997, when the first Regulation on novel foods came into force, is considered as “Novel Food” and controlled in a stricter manner than regular foods under Regulation (EU) 2015/2283 (“the Novel Food Regulation”).”

“Food producers can place a Novel Food on the EU market only after the European Commission has processed an application for the authorisation of the novel food, has adopted an implementing act authorising its placing on the market and updated the EU list of novel foods.”

“A food or ingredient will be authorised only if it meets the criteria laid out in Article 7, namely it is shown to be safe, not nutritionally disadvantageous and does not mislead the consumer.”

“There are three routes by which an apparently novel food may be approved or authorised under the Novel Food Regulation:

  1. by showing the food’s significant history of use in the EU prior to 1997, through the official consultation procedure provided for in Article 4 (i.e. that the food or ingredient is not, in fact, a Novel Food); or
  2. as a traditional food from a third country in accordance with Article 15, where a history of safe food use for at least 25 years can be demonstrated; or
  3. a full application based on submission of a dossier for registration of a Novel Food in accordance with Articles 10-13.”

“The EU Novel Food Catalogue lists foods and ingredients viewed as novel foods, for which an authorisation should be obtained. The Catalogue itself, has no legal status, but is frequently used by EU Member States to assist in enforcement of the Novel Food Regulation.”

“The cultivation of Cannabis sativa L. varieties is permitted in the EU provided they are registered in the EU’ The European Commission’s Working Group of Novel Foods has recently reclassified CBD as a Novel Food for the purposes of the EU Novel Food Catalogue.”

This currently states in relation to Cannabis sativa L.” “Some products derived from the Cannabis sativa plant or plant parts such as seeds, seed oil, hemp seed flour, defatted hemp seed have a history of consumption in the EU and therefore, are not novel. Other specific national legislation may restrict the placing on the market of this product as a food or food ingredient in some Member States. Therefore, it is recommended to check with the national competent authorities”.

“The entry for cannabinoids now states: ‘[…] extracts of Cannabis sativa L. and derived products containing cannabinoids are considered novel foods as a history of consumption has not been demonstrated. This applies to both the extracts themselves and any products to which they are added as an ingredient (such as hemp seed oil). This also applies to extracts of other plants containing cannabinoids. Synthetically obtained cannabinoids are considered as novel’.”

“As a result of this change, the European Commission now regards all extracts of hemp and derived products containing cannabinoids (including CBD) as novel. Hemp seeds, flour and seed oil remain excluded from the categorisation of Novel Foods in the Catalogue, as long as cannabinoids have not been added as ingredients. While, as stated above, the Catalogue has no legal status, in practice it will be given substantial weight by national authorities, who may therefore conclude that foods containing CBD may be placed on the EU market only once an authorisation under the Novel Foods Regulation has been obtained. Nevertheless, the current approach to CBD, at Member State level, following the amendment to the Novel Foods Catalogue, is variable:”

“The Irish Food Safety Authority considers CBD products based on the manufacturing process applied. CBD oil prepared through cold-pressing of hemp seeds, may be sold on the basis that this oil contains low levels of CBD. In contrast, CBD obtained through methods such as supercritical CO2 extraction, would be viewed as Novel Foods for which an authorisation is required. Other authorities (e.g. those in Belgium and Austria) do not permit CBD products to be marketed.”

“A novel food application for CBD is currently under consideration with the European Food Safety Authority (EFSA) to authorise the use of CBD in food supplements for adults with a daily intake of up to 130 mg. This application was made by Cannabis Pharma s.r.o., a company from the Czech Republic and is based on publicly available safety and toxicological information and toxicity reviews. The opinion of the EFSA is reportedly expected soon. This decision will be closely monitored by the industry as it may have wider significance for the CBD food products market. CBD food products lawfully on the market prior to 1 January 2018 may rely on the transitional provisions of the Novel Foods Regulation. As long as an application for an authorisation is filed before 2 January 2020, the product can continue to be marketed until an authorisation decision has been taken by the Commission.”

“The status of foods containing CBD also determines the claims that may be made when they are marketed. If such products qualify as foods or food supplements, only specific health or nutrition claims authorised in the EU Register in accordance with Regulation (EC) No 1924/2006 may be made. Any CBD product taken for a medical purpose and associated with medical claims must be authorised as medicinal products.“

The current position of the United Kingdom Food Standards Agency (last updated on the web, May 2018) appears to be “The FSA accepts the clarification from the EU that CBD extracts are considered novel foods. We are committed to finding a proportionate way forward by working with local authorities, businesses and consumers to clarify how to achieve compliance in the marketplace in a proportionate manner’. “ Also see: https://www.medicpro.london/cbd-regulation-laws-uk/

The Cannabis Trades Association:

According to their web site, The Cannabis Trades Association, previously known as The Hemp Trades Association UK Limited, as of September 2018, represents around 900 members (and growing) and around 3000 sellers from 19 EU states, America and Canada making it the largest body of its kind anywhere in the world. In 2018 its members sold around $1.7bn of products worldwide and around €480m of products in Europe.

According to the CTA “in June 2017, the Food Standards Agency (FSA) contacted the CTA as it was intending to review the status of CBD extracts and placing them under the Novel Foods Regulation (CBD has been on the Novel Register since 2014). Classifying CBD extracts as Novel Foods, and not food supplements anymore, would create a very restrictive control on how CBD products could be offered to the market, thus stopping the sales of an industry that had witnessed a 100% growth in the previous 6 months.”

“The CTA responded by triggering a series of meetings with the FSA and the head of the Novel Foods section. The goal was to objectively demonstrate that CBD products were historically not Novel and that the need to restrict their sales through demanding regulation was not appropriate. The CTA also insisted on the difference between extracts and isolates. While extracts are obtained using centuries-old methods, isolates use modern technology that did not exist prior to 1997 in order to achieve significantly usable results.”

The CTA continued at its web site: “The CTA and FSA quickly reached a shared position that only saw isolated cannabinoids as Novel Foods, leaving extracts under the foods supplement rules. This successful conclusion ensured on one side that the industry could continue to thrive and grow while selling extracts-based products; it also ensured, on the other side, that the FSA could set its rules and regulations in partnership with a knowledgeable body. This event also raised consciousness about the need of a true self-regulating organisation for the CBD market. The Cannabis Products Directive (CPD), now evolved into TrustCanna, was born. Of course, since then further actions in Europe have seen a tightening from the position we faced then. Now we are dealing extensively with the FSA and other equivalent bodies on a legal route to ensure that non-exclusive cannabinoid extracts are not seen as Novel. October will see the CTA launch a legal process to ensure that only isolated cannabinoid compounds are seen as Novel.”

(NOTE: The inconsistencies between what the CTA’s position, and the positions of the MHRA and the Home Office, which are described in detail earlier in this memorandum. The inconsistencies, relate in part to the virtual impossibility of getting THC concentrations down to below 1 milligram per saleable quantity of CBD extracted product.)

Also see: Stop Notices Novel Foods and Local Councils. At that portion of its web site, the CTA states: “In December 2018, a London Borough Trading Standards officer issued a Stop Notice to a CTA member under Novel Foods. This was apparently first of its kind in the UK. This notice risked placing a newly established member out of business, just a few weeks after opening in a prominent and visible location. It was also a negative precedent for the industry that should not be allowed to be set. The CTA engaged its legal team and helped the member while addressing the local Trading Standards worries. The local Trading Standards officer lifted the stop notice and the member could resume business operations. The CTA has since helped other members in similar situations with Trading Standards. The stop notices were rescinded in all cases.

The CTA is the only organisation of its kind that has since become proactive and is now training Trading Standards officers, with the goal of preventing stop notices based on lack of knowledge.”

On September 2, 2019, the CTA issued the following press release: 

“Following the changes to the Novel Foods Regulations and the uncertainty as to if the scope of the regulations would include all cannabinoids and extracts of cannabis. The Cannabis Trades Association is opposed to submitting a Novel Foods Application covering these extracts. Embarking on this application process would mean that the products detailed, within any products, would have to come off the market until such a time as an authorization is granted as the transitional measures to allow the continued sale ended on the 1st Jan 2019. The Cannabis Trades Association would like to confirm:

“While there is no need for Novel Foods applications to be made for cannabis extracts, there is a real need within the industry for legal clarification that extracts are not Novel. As such, following discussions with the EFSA and SANTE, we are proposing a legal route to reach a final determination which has the backing of several Member States in this course of action, all of whom have been visited personally. As part of this process, which is a legal and fully verified action, the CTA will ask all committee members of the Novel Foods Working Group to agree to a process by which it would be unlawful to proceed with any enforcement action against any CTA member. As such, ensuring that only products and sellers registered with the Association are proven to be by the legal team’s opinion safe and legal. We will provide data to every EU member state to show that our members are selling compliantly and that their products are fully compliant with what we believe is not a Novel Food. As another part of the process, we will also introduce TrustCanna, an independent expert panel regulating and registering sellers and products to the Member States. TrustCanna already has a number of companies and products going through registration. TrustCanna is a Cannabis Product certification process that certifies that a product is safe, legal and as described. TrustCanna aims to provide consumers with a single register of all products that will enable them to make informed purchasing decisions from safe ethical suppliers of cannabis products. From farmers, to producers, manufacturers and resellers. Any business in the supply chain can register and TrustCanna certify their products as compliant. Comments may be sought from:

Robert Jappie, Head of Cannabis Law, Mackrell Turner – 020 7240 0521 Hugh McKeown, CEO TrustCanna 07946 253523.” According to Reed Smith “Accordingly, in England, local authorities will have the power under the Novel Foods (England) Regulations 2018 to seize and inspect suspected unauthorised novel foods and issue compliance and stop notices requiring a product to be removed from sale – for instance, when there is reason to suspect it could be harmful to consumers – and to impose fines. The European Food Standards Agency, which is responsible for food safety in the European Union, is currently considering the first novel food application for CBD.”

(https://www.reedsmith.com/en/perspectives/2019/08/cannabis-in-the-uk–a-regulatory-environment-in-transition )

6.  The Centre for Medicinal Cannabis

The Centre for Medicinal Cannabis is an association in the UK composed of numerous medical and scientific professionals and others involved in the area of Medicinal Cannabis. In the area of CBD, in order to support our members, active in the CBD wellness sector, the CMC undertook the most thorough analysis of the UK CBD market to date. The CMC states that it found that the market was much larger than had previously been suggested, larger than that of vitamin C and D combined, and had great potential for growth. Through testing, the CMC also discovered that the quality of products varied wildly. It is also the view of the CMC that inaccurate information is being circulated in this sector leading to confusion over what is actually legal.

I quote a number of comments from the summary to the study. I agree with virtually all of the comments in the study, in the areas where I have some knowledge.

Extracts from the Report:

The Law:

January 2019. As currently drafted, it presents a serious challenge to the CBD market as it exists in the UK today – however it is yet to be enforced in the UK.”

The Regulations:

(Not clear to me what this means.)

The Consumer:

The Market:

Author: Joshua Neilly
CEO
Bloom Botanics
Is It Legal To Grow CBD Plants In The UK?

As you may know, the CBD industry in the United Kingdom has been growing at exponential rates since its legalisation in late 2018. However, to this day, CBD and Hemp laws in the UK are still confusing as ever. It also doesn’t help that many people still mix up Hemp and Cannabis for the same thing. 

Others, who may already know the distinction between the two, might just think that because Hemp is non-psychoactive, that it is totally ok to grow a few plants for personal use, right? Unfortunately, that is not the case, and it is actually a little trickier than that.  

Anxious About UK CBD Law? Don’t MissUK CBD LAW – AN IN-DEPTH ANALYSIS

Recently, many people have been questioning whether or not it is legal to grow their own hemp plants for CBD, which plants are legal to grow and whether or not you can make your own CBD at home. For that reason, we have compiled here a few of these questions, and hope to clear up any questions and doubts for you.

Key Sections:

Hemp Plants

What are CBD Plants?

First of all, it is important to know that CBD comes from both hemp and marijuana plants. That’s because they are the same plants. Varieties of Cannabis plants containing traceable amounts of THC (around less than 0.2%) are known as Hemp plants. While marijuana refers to varieties of Cannabis plants containing higher amounts of THC.

Cannabis (Marijuana) v.s. Hemp Plants

Apart from psychoactive effects, there are also a few other differences between hemp and marijuana plants. Even though they are both from the Cannabis family, they look and grow different. Hemp leaves are thinner and are concentrated near the top of the stalk. The plant itself is very tall and slender, so thanks to this, it can be grown much closer together. 

Hemp is very hardy and can be grown pretty much anywhere, while marijuana requires a carefully controlled environment or a hot and humid climate. Hemp is grown and used for multiple purposes: consumption, textiles and even building materials. While marijuana is grown for medicinal and can not be used for textiles since it’s fibre has a low tensile strength. 

If the hemp is meant to be used for consumption, cultivators must be careful about where they grow their hemp as it can absorb any of the toxins in the soil. However, this isn’t always a negative, as it improves soil fertility by fixing nitrogen and isolating carbon. Making it extremely industrious and sustainable. 

As mentioned before, the main and biggest difference between the two is the THC content. In the UK, there are still numerous laws against the personal use, growth, or distribution of the cannabis plant in the United Kingdom. 

Hemp Vs Marijuana

Is it Legal to Grow Cannabis and Hemp Plants?

When it comes to this particular subject, there are two different categories which separate the answer to this question. The first is whether or not it is legal to grow cannabis and hemp plants at home, and the other is whether or not it is legal for companies to grow cannabis and hemp plants.

Legality of Growing Cannabis and Hemp Plants at Home

Growing your own plants at home to make your own CBD sounds quite appealing to many people in the UK. But there are a few laws regarding this issue that prevent the average person from simply growing their own plants for CBD.

For one thing, growing cannabis (marijuana) plants is still forbidden by the law, as you read above, due to its high content of THC, which remains an illegal substance in the United Kingdom, as per the Misuse of Drugs Act of 1971.

Therefore, growing your own cannabis plants in the UK is definitely a no-go in the eyes of the law. In fact, just being caught with cannabis in the UK is penalised by up to 5 years in prison, by an unlimited fine or even both.

Additionally, being caught producing and distributing marijuana (or any other Class-B drugs) in any way is penalised with up to 14 years in prison, an unlimited fine, or both. For this reason, we very strongly advise against even considering this as an option.

You may be surprised to find that Hemp is equally as illegal in the UK as cannabis is and can only be grown for commercial purposes with a license. Meaning, you cannot grow it for personal use at all. Again, we strongly advise against doing this. It may seem that just because there is a low THC content, then it should be fine, but is it really worth all the legal repercussions? 

Our suggestion? Just go online, do some research about CBD brands and the different ways you can take CBD, and buy CBD products from your favourite shop in a matter of seconds. Not only will you find much better quality CBD, but you will be much safer.

Hemp plant growing in the wild

Legality of Growing Cannabis and Hemp Plants as a Company

Naturally, CBD must be sourced from either Cannabis sativa plants or Cannabis sativa L. plants. Therefore, in order to produce and distribute products which contain CBD, certain standards need to be meet and you need a license to grow Hemp and Cannabis.

A number of different documents and presentations must be presented in order to even be considered as a potential receiver of an industrial hemp license. Then they must go through a Disclosure and Baring Service (DBS) check. You also have to pay a fee with your application. New licences usually cost £580, with licence renewals costing £326. 

Then, when the license is granted, there are still a number of rules and regulations in which these companies must follow in order to ensure the public’s safety and well-being. For example, the plant can’t be grown in the vicinity of schools or areas of public access and you also have to tell your local police where you’ll be growing hemp.

However, even after following all of the strict rule and regulations for growing industrial hemp, it is still extremely hard to get a license that allows cultivators to harvest hemp flowers for CBD. At the moment, there is only one farm in Jersey in all of the UK that is able to harvest hemp flowers for Cannabidiol. Meaning, most of the CBD products bought has been made with European hemp cultivated outside of the UK. 

Some of the Home Office rules for growing industrial hemp include:

You can find out more about growing industrial hemp in the UK on the Government hemp licensing page.

Growing cannabis (marijuana) is a much more difficult process since marijuana is only allowed to be grown with a special license and for medicinal purposes. Finding information on how to do so is quite difficult as the guidance for the Cannabis-based medicines expert panel with the Home Office was withdrawn on the 26 July 2019.

The FDA (Food and Drug Administration) and the MHRA (Medicines and Healthcare products Regulatory Agency) have put many rules down for companies to follow in order for there to be a stronghold on both quality control and on substance distribution.

Processed hemp products can be legally traded and used in the UK as a food supplement without a license if their THC content is 0.2%. Achieving this percentage can be quite trying for the normal person, but CBD brands have all the necessary equipment for this process and can do it all in a short time. Not to mention, they have the technology needed for testing and making sure all their CBD contains less than the legal 0.2% limit of THC.